GlobeNewswire

Oxford Immunotec Reports Second Quarter 2018 Financial Results

Del
  • Second quarter Tuberculosis (TB) revenue growth of 17%, with record TB revenue in the United States
  • Gross margin improved by 450 basis points compared to prior year period and 630 basis points on a sequential basis
  • Launch of transformative T-Cell Select™ product to enable full automation of T-SPOT®.TB test

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced second quarter 2018 financial results.

“We are pleased with our second quarter performance, which included a strong uptick in TB revenue growth, robust gross margin expansion, and continued progress advancing the company towards profitability,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec.

By revenue type, total revenues were, in millions:

  Three Months Ended June 30,
  2018
  2017
  Percent
Change

                         
Product $   11.7     $   10.4     12 %
Service     17.6         15.7     12 %
Total Revenue $    29.3     $      26.1     12 %
           

By indication, total revenues were, in millions:

  Three Months Ended June 30,
   2018    2017   Percent
Change

                         
Tuberculosis $   25.0     $   21.3     17 %
Tick-Borne Disease and Other     4.3         4.8     -9 %
Total Revenue $     29.3     $     26.1     12 %
           

By geography, total revenues were, in millions:

  Three Months Ended June 30,
                      Percent Change
  2018
  2017
  As Reported
  Constant
Currency
(1)
                               
United States $   17.7     $   16.1     10 %   10 %
Europe & ROW     2.2         1.9     17 %   10 %
Asia     9.4         8.1     16 %   15 %
Total Revenue $     29.3     $     26.1     12 %   11 %
               

(1) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

Second Quarter 2018 Financial Results

Revenue for the second quarter of 2018 was $29.3 million, representing a 12% increase from second quarter 2017 revenue of $26.1 million. On a constant currency basis, revenue growth was 11% versus the prior year period. Tuberculosis revenue for the second quarter of $25.0 million increased 17% over the prior year period. 

2018 second quarter product revenue was $11.7 million, representing a 12% increase from product revenue of $10.4 million in the second quarter of 2017. The increase was attributable to strong growth in both Asia and Europe & ROW. Service revenue for the second quarter of 2018 was $17.6 million, up 12% from 2017 second quarter service revenue of $15.7 million. The increase in service revenue was primarily driven by increased tuberculosis revenues in the United States and United Kingdom.

United States revenue was $17.7 million in the second quarter of 2018, representing a 10% increase from revenue of $16.1 million in the prior year period. The increase was due to growth in our core tuberculosis business, which was partially offset by an expected decline in blood donor screening revenue.

Europe & ROW revenue was $2.2 million in the second quarter of 2018, representing a 17% increase compared to the second quarter of 2017. On a constant currency basis, Europe & ROW revenue increased 10% versus the second quarter of 2017. The increase was driven by strong tuberculosis revenue growth in core European markets, especially in the United Kingdom.

Asia revenue was $9.4 million in the second quarter of 2018, representing an increase of 16% compared to 2017 second quarter revenue of $8.1 million. On a constant currency basis, Asia revenue increased 15% versus the second quarter of 2017.

Gross profit for the second quarter of 2018 was $16.6 million, an increase of approximately $3.0 million from gross profit of $13.6 million in the same period of 2017. Gross margin was 56.7%, an increase of 450 basis points from gross margin of 52.2% in the second quarter of 2017. The increase in gross margin was primarily the result of lower royalty expenses, product mix, and continued operating improvements.

Operating expenses were $21.4 million in the second quarter of 2018, a decrease of approximately $10.0 million compared to $31.4 million in the second quarter of 2017. Excluding settlement and other one-time items in both periods, operating expenses for the second quarter of 2018 decreased approximately $2.2 million compared to the second quarter of 2017.

Net loss for the second quarter of 2018 was $6.5 million, or $0.25 per share, compared to $16.8 million, or $0.74 per share, in the second quarter of 2017. Net loss per share was based on 25,845,124 and 22,805,379 weighted average ordinary shares outstanding for the second quarters of 2018 and 2017, respectively. 

EBITDA for the second quarter of 2018 was $(4.0) million compared to $(17.4) million in the second quarter of 2017. Adjusted EBITDA was $(1.8) million for the second quarter of 2018 compared to $(6.3) million in the same period in 2017. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Business Outlook

We continue to expect to report full year 2018 revenue of between $112 and $115 million, representing 9% - 12% year-over-year growth as reported.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, July 31, 2018 at 8:00 a.m. Eastern Time to discuss its second quarter 2018 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 9268558 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT, T-Cell Select and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACTS:

For Media and Investor Inquiries:
Karen Koski
VP, Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)
 
    Three months ended June 30,   Six months ended June 30,
(in thousands, except share and per share data)     2018       2017       2018       2017  
Revenue                
Product   $   11,721      $   10,422      $   19,656      $   18,808   
Service       17,597          15,698          31,032          28,817   
Total revenue       29,318          26,120          50,688          47,625   
Cost of revenue                
Product       3,477          4,094          6,051          7,339   
Service       9,229          8,398          17,245          15,650   
Total cost of revenue       12,706          12,492          23,296          22,989   
Gross profit       16,612          13,628        27,392          24,636   
Operating expenses:                
Research and development       3,385          3,948          7,129          7,753   
Sales and marketing       9,308          10,041          18,713          19,681   
General and administrative       7,116          7,990          14,044          14,866   
Change in fair value of contingent purchase price consideration       —          (238 )       —          (2,595 )
Settlement expense       1,560          9,635          1,767          9,635   
Total operating expenses       21,369          31,376          41,653          49,340   
Loss from operations       (4,757 )       (17,748 )       (14,261 )       (24,704 )
Other expense:                
Interest expense, net       (733 )       (807 )       (1,337 )       (1,630 )
Foreign exchange losses       (151 )       (547 )       (254 )       (653 )
Other expense       (196 )       (122 )       (248 )       (262 )
Loss before income taxes       (5,837 )       (19,224 )       (16,100 )       (27,249 )
Income tax (expense) benefit       (634 )       2,458          (697 )       2,411   
Net loss   $   (6,471 )   $   (16,766 )   $   (16,797 )   $   (24,838 )
                 
Net loss per ordinary share—basic and diluted   $   (0.25 )   $   (0.74 )   $   (0.65 )   $   (1.10 )
                 
Weighted-average shares used to compute net loss per ordinary share—basic and diluted       25,845,124          22,805,379          25,782,366          22,670,206   
                 


Reconciliation of net loss to Adjusted EBITDA (1)
(unaudited)
 
    Three months ended June 30,   Six months ended June 30,
(in thousands)     2018       2017       2018       2017  
Net loss   $ (6,471 )   $ (16,766 )   $ (16,797 )   $ (24,838 )
Income tax expense (benefit)     634        (2,458 )     697        (2,411 )
Interest expense, net     593        667        1,057        1,341   
Depreciation and amortization of intangible assets     1,110        990        2,243        1,993   
Accretion and amortization of loan fees     140        140        280        289   
EBITDA     (3,994 )     (17,427 )     (12,520 )     (23,626 )
                 
Reconciling items:                
Share-based compensation expense     922        1,434        2,746        2,760   
Unrealized exchange (gains) losses     (323 )     319        (482 )     281   
Change in fair value of contingent purchase price consideration             (238 )             (2,595 )
Settlement expense     1,560        9,635        1,767        9,635   
Adjusted EBITDA   $ (1,835 )   $ (6,277 )   $ (8,489 )   $ (13,545 )

(1) EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)
         
    June 30,   December 31,
(in thousands, except share and per share data)     2018       2017  
Assets        
Current assets:        
Cash and cash equivalents   $ 66,263      $ 90,332   
Accounts receivable, net     19,742        16,981   
Inventory, net     9,835        10,142   
Prepaid expenses and other assets     4,088        3,027   
       
Total current assets     99,928        120,482   
Restricted cash, non-current     200        200   
Property and equipment, net     12,712        9,067   
Goodwill     3,967        3,967   
Other intangible assets, net     7,521        7,849   
Deferred tax asset     1,435        2,486   
Other assets     181        185   
         
Total assets   $ 125,944      $ 144,236   
         
Liabilities and shareholders’ equity        
Current liabilities:        
Accounts payable   $ 4,186      $ 6,842   
Accrued liabilities     9,754        11,134   
Settlement liability     4,451        4,342   
Deferred income     46        36   
Current portion of loans payable     94        91   
         
Total current liabilities     18,531        22,445   
Long-term portion of loans payable     30,136        29,904   
Settlement liability     3,991        3,894   
Other liabilities     122        364   
         
Total liabilities     52,780        56,607   
         
Shareholders’ equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at June 30, 2018 and December 31, 2017, and 25,957,954 and 25,661,634 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively     272        269   
Additional paid-in capital     297,906        294,613   
Accumulated deficit     (218,338 )     (201,541 )
Accumulated other comprehensive loss     (6,676 )     (5,712 )
         
Total shareholders’ equity     73,164        87,629   
         
Total liabilities and shareholders’ equity   $ 125,944      $ 144,236   
         

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi